Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

Resource Type

CF Research News

Authors

Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC; KLIMB study group.

References

J Cyst Fibros. 2019 Apr 30. pii: S1569-1993(19)30061-X. doi: 10.1016/j.jcf.2019.03.009.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

CFTR potentiator [3]
Ivacaftor [4]
KLIMB [5]
Pediatrics [6]
Safety [7]

Date

Tuesday, April 30, 2019

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [8]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/open-label-extension-study-ivacaftor-children-cf-and-cftr-gating

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-19-00047R1_FINAL_Davies_070919.pdf [2] https://www.ncbi.nlm.nih.gov/pubmed/31053538 [3] https://www.ecfs.eu/research-article-keywords/cftr-potentiator [4] https://www.ecfs.eu/research-article-keywords/ivacaftor [5] https://www.ecfs.eu/research-article-keywords/klimb [6] https://www.ecfs.eu/research-article-keywords/pediatrics [7] https://www.ecfs.eu/research-article-keywords/safety [8] https://www.ecfs.eu/resource-guideline-type/other-guidelines